130 completed, 36 terminated, 28 recruiting, 26 unknown. 178 Phase 2, 49 Phase 1, 28 Phase 3, 2 Early Phase 1, 2 Phase 4.
Follow Panitumumab: new trials by email Literature Review of Panitumumab trials Research Report on Panitumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-10-31 | 2026-10-13 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer VS-7375, cetuximab, panitumumab - Colorectal Cancer | Phase 2 | Recruiting | Verastem, Inc. | 150 | 2026-07-28 | 2026-10-26 |
| 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC 89Zr-panitumumab IV, Panitumumab - Head-and-neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Andrei Iagaru | 2026-06-01 | 2026-08-17 | |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 94 | 2026-05-13 | 2026-05-22 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation Sotorasib, Panitumumab - Advanced Solid Tumors | Phase 2 | Recruiting | Amgen | 14 | 2026-01-02 | 2026-07-23 |
| A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. ERAS-4001, ERAS-4001 in combination - Metastatic Solid Tumors | Phase 1 | Recruiting | Erasca, Inc. | 200 | 2025-08-06 | 2025-12-03 |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors AMG 410, Pembrolizumab, Panitumumab - KRAS Altered Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Amgen | 434 | 2025-07-31 | 2026-07-30 |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors ASP5834, panitumumab - Solid Tumor, Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Astellas Pharma Inc | 404 | 2025-07-25 | 2026-10-29 |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors ERAS-0015, ERAS-0015 in combination - Metastatic Solid Tumors | Phase 1 | Recruiting | Erasca, Inc. | 600 | 2025-06-05 | 2026-09-01 |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin - Metastatic Colorectal Cancer | Phase 2 | Recruiting | AbbVie | 390 | 2025-04-24 | 2026-10-27 |
| A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI RPH-030, Vectibix®, Irinotecan - Metastatic Colorectal Cancer | Phase 1 | Recruiting | R-Pharm | 180 | 2025-04-17 | 2026-04-22 |
| Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 73 | 2025-03-21 | 2025-12-10 |
| ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer irinotecan, panitumumab, Valproic Acid (VPA) - Colorectal Cancer Metastatic | Phase 2 | Recruiting | National Cancer Institute, Naples | 130 | 2025-03-12 | 2025-12-17 |
| A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms | Phase 2 | Recruiting | Blokhin's Russian Cancer Research Center | 64 | 2025-03-01 | 2025-05-18 |
| Botensilimab and Balstilimab Optimization in Colorectal Cancer Botensilimab, Balstilimab, Oxaliplatin - Colorectal Cancer | Phase 2 | Active not recruiting | Nicholas DeVito, MD | 16 | 2024-11-18 | 2026-02-05 |
| The Sagittarius Trial Oxaliplatin, Capecitabine, Folinic acid - Colon Cancer Stage II, Colon Cancer Stage III | Phase 3 | Recruiting | IFOM ETS - The AIRC Institute of Molecular Oncology | 700 | 2024-10-22 | 2025-08-29 |
| Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study FOLFOXIRI Protocol - Neoplasm Malignant, Colon Cancer Stage 4 | Phase 2 | Unknown | Al-Azhar University | 60 | 2024-08-17 | 2024-08-28 |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2024-08-01 | 2026-10-22 |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation FOLFIRI Regimen, Sotorasib, Panitumumab - Metastatic Colorectal Cancer | Phase 3 | Recruiting | Amgen | 450 | 2024-07-17 | 2026-09-03 |
Showing 20 of 243. Sign in to see all of them.
Colorectal Neoplasms (120) · Colonic Neoplasms (30) · Neoplasm Metastasis (28) · Neoplasms (27) · Rectal Neoplasms (27) · Carcinoma, Non-Small-Cell Lung (15) · Esophageal Neoplasms (10) · Head and Neck Neoplasms (9) · Pancreatic Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (9) · Lung Neoplasms (8) · Cholangiocarcinoma (7) · Breast Neoplasms (6) · Carcinoma, Squamous Cell (6) · Carcinoma (5)
Amgen (40) · M.D. Anderson Cancer Center (7) · Gruppo Oncologico del Nord-Ovest (6) · Vejle Hospital (6) · AIO-Studien-gGmbH (5) · Grupo Espanol Multidisciplinario del Cancer Digestivo (5) · Takeda (5) · UNICANCER (5) · Federation Francophone de Cancerologie Digestive (4) · Memorial Sloan Kettering Cancer Center (4) · National Cancer Institute, Naples (4) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (4) · WiSP Wissenschaftlicher Service Pharma GmbH (4) · Alliance for Clinical Trials in Oncology (3) · Jonsson Comprehensive Cancer Center (3)
United States (102) · Italy (28) · Spain (27) · France (26) · Germany (23) · Belgium (14) · Canada (14) · Australia (13) · Japan (13) · Netherlands (13) · United Kingdom (12) · Denmark (9) · Austria (8) · South Korea (8) · Greece (7)
Anders Jakobsen, DMSc (2) · Anders Jakobsen, MD, DMSc (2) · Antonio Arrivi, MD (2) · Aram Hezel, MD (2) · Arie Belldegrun, MD, FACS (2) · Gerri Lee (2) · Hagen Kennecke, MD (2) · Jaime Feliu, MD (2) · Joan Maurel, MD (2) · Jorge Aparicio, MD (2)
PMID 26049686, PMID 22070868, PMID 18316791, PMID 29627309, PMID 34213592, PMID 28237539, PMID 30679026, PMID 31378656, PMID 31515083, PMID 37596461, PMID 38347302, PMID 38592721, PMID 10744089, PMID 10918161, PMID 11247898, PMID 15175435, PMID 15210739, PMID 15870084, PMID 16943526, PMID 17470860, PMID 17671985, PMID 17785764, PMID 18407737, PMID 18506163, PMID 19097774, PMID 19203894, PMID 19287023, PMID 19339720, PMID 19755046, PMID 21090969, PMID 22000810, PMID 22210091, PMID 22367707, PMID 23041588, PMID 23139259, PMID 23359181, PMID 23504398, PMID 23594787, PMID 23625191, PMID 23725851, PMID 23953030, PMID 24138831, PMID 24146220, PMID 24562448, PMID 24819684, PMID 24827135, PMID 25596660, PMID 25633805, PMID 25772756, PMID 25943574
2009 (14), 2016 (5), 2017 (4), 2008 (3), 2025 (3), R01CA190306 (3), U10CA180820 (3), 2015 (2), 2023 (2), P30CA015083 (2), 2014 (1), P30CA014089 (1), P30CA016086 (1), P30CA036727 (1), P30CA060553 (1)